Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Stephen J Kerr, Andrea Mant, Fiona E Horn, Kevin McGeechan and Geoffrey P Sayer
Med J Aust 2004; 180 (6): . || doi: 10.5694/j.1326-5377.2004.tb05939.x
Published online: 15 March 2004

Stephen J Kerr,* Andrea Mant, Fiona E Horn, Kevin McGeechan,§ Geoffrey P Sayer

  • 1 National Prescribing Service, PO Box 1147, Strawberry Hills, NSW 2012
  • 2 Quality Use of Medicines, South East Health, Sydney Hospital, Sydney, NSW
  • 5 Health Communication Network, St Leonards, NSW.


Competing interests:

In 1997, Associate Professor Andrea Mant provided consultancy advice on Quality Use of Medicines to Merck Sharp & Dohme.

  • 1. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328-331. <eMJA full text>
  • 2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
  • 3. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283-292.
  • 4. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795-806.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.